晚期肾癌靶向治疗的现状与进展

Current status and progress in the targeted therapy for advanced renal cell carcinoma

随着对肾癌发生发展过程的分子信号通路研究的不断深入,晚期肾癌的靶向治疗取得了重大进展。曾作为标准的细胞因子治疗效果不佳且有明显毒副作用,而靶向治疗已显示出在治疗晚期肾癌方面的明显优势。本文对舒尼替尼、索拉非尼、贝伐单抗、帕唑帕尼、Temsirolimus、依维莫司六种靶向药物的临床疗效,毒副作用以及对策,在贯序治疗、联合治疗和新辅助治疗方面的进展作一综述。

Advances in understanding of the intracellular molecule signalling pathways of renal cell carcinoma have led to the development of targeted therapies for advanced renal cell carcinoma. Previously the systemic approaches were limited to cytokine therapies that were modest in their clinical benefits and at the expense of significant toxiei- ties. The development of targeted therapy has revolutionized the treatment of advanced renal cell carcinoma with more meaningful outcomes. This review aims to review the clinical benefits and toxicities of targeted drugs such as sunitinib,sorafenib,bevacizumab,pazopanib, temsirolimus and everolimus. Current status and progresses are summa- rized in sequential therapies and potential combination therapies, as well as neoadjuvant therapies.